CytoAgents Revenue and Competitors
Estimated Revenue & Valuation
- CytoAgents's estimated annual revenue is currently $852.5k per year.
- CytoAgents's estimated revenue per employee is $77,500
- CytoAgents's total funding is $10.2M.
Employee Data
- CytoAgents has 11 Employees.
- CytoAgents grew their employee count by -15% last year.
CytoAgents's People
| Name | Title | Email/Phone |
|---|
CytoAgents Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.4M | 9 | -10% | N/A | N/A |
#2 | $7.1M | 46 | 77% | N/A | N/A |
#3 | $14.4M | 93 | 27% | N/A | N/A |
#4 | $0.9M | 6 | 0% | N/A | N/A |
#5 | $1.6M | 10 | 43% | N/A | N/A |
#6 | $11.5M | 74 | 6% | N/A | N/A |
#7 | $0.9M | 11 | 22% | N/A | N/A |
#8 | $3.7M | 24 | -8% | N/A | N/A |
#9 | $2M | 13 | 18% | N/A | N/A |
#10 | $9.3M | 60 | 2% | N/A | N/A |
What Is CytoAgents?
CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. There are many causes of CRS and our mission is to develop a broadly accessible treatment for multiple indications of high unmet need. Using a novel approach by calming the natural immune response to a multi organ disease, CytoAgemts' lead drug candidate, GP1681, is positioned to become a new best practice in medicine.
keywords:N/A
$10.2M
Total Funding
11
Number of Employees
$852.5k
Revenue (est)
-15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CytoAgents News
cytoagents.com, $100,000, 5, $100,000, Clinical stage biotechnology company focused on the development of innovative pharmaceutical products...
Other Companies in Pittsburgh
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1M | 11 | 175% | N/A |
#2 | $1.7M | 11 | -15% | N/A |
#3 | $3.5M | 11 | -21% | N/A |
#4 | $1M | 11 | 83% | N/A |
#5 | $1M | 11 | 38% | N/A |